Literature DB >> 8100409

Is the association between inhaled beta-agonist use and life-threatening asthma because of confounding by severity?

P Ernst1, B Habbick, S Suissa, B Hemmelgarn, D Cockcroft, A S Buist, R I Horwitz, M McNutt, W O Spitzer.   

Abstract

We have previously reported an increasing dose-response relationship between the regular use of beta-agonist inhalers and the risk of asthma death and near death among a cohort of 12,301 subjects who had been dispensed 10 or more prescriptions of asthma drugs from January 1980 to April 1987. That analysis was based solely on information obtained from linkable computerized data bases. Such an association might be explained in part by the tendency of patients with more severe asthma, that is, those at greatest risk for an adverse outcome, to use more beta-agonist medication. To further examine this potential confounding by severity, we gathered clinical information independently from the field on the 129 case patients and their 655 control patients from the matched case-control analysis of 12,301 subjects. In 68% of the control patients with a life-threatening episode and 75% of the matched control subjects, we obtained a valid questionnaire from at least one physician who had seen the patient during the previous 2 yr. Acceptable information on hospitalizations because of asthma was obtained in 87% of those hospitalized. Clinical features associated with an increased risk of fatal and near-fatal asthma were: a history of loss of consciousness or seizures during a previous asthma attack (odds ratio, 10.2; 95% CI, 3.9 to 26.7), a history of attacks of asthma precipitated by eating certain foods (odds ratio, 5.1; 95% CI, 2.4 to 11.1), a clinical score designed to reflect the severity of prior attacks of asthma leading to hospitalization, and prior respiratory acidosis among those in whom a blood gas determination was recorded.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8100409     DOI: 10.1164/ajrccm/148.1.75

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  18 in total

1.  Guidelines do matter.

Authors:  N Anthonisen
Journal:  CMAJ       Date:  2001-03-06       Impact factor: 8.262

Review 2.  Long- versus short-acting beta 2-agonists. Implications for drug therapy.

Authors:  L P Boulet
Journal:  Drugs       Date:  1994-02       Impact factor: 9.546

Review 3.  Clinical management of asthma in the 1990s. Current therapy and new directions.

Authors:  P Jain; J A Golish
Journal:  Drugs       Date:  1996       Impact factor: 9.546

Review 4.  Canadian Asthma Consensus Report, 1999. Canadian Asthma Consensus Group.

Authors:  L P Boulet; A Becker; D Bérubé; R Beveridge; P Ernst
Journal:  CMAJ       Date:  1999-11-30       Impact factor: 8.262

Review 5.  Drug treatment of asthma in the elderly.

Authors:  S S Braman
Journal:  Drugs       Date:  1996-03       Impact factor: 9.546

Review 6.  Asthma and the beta agonist debate.

Authors:  J Crane; N Pearce; C Burgess; R Beasley
Journal:  Thorax       Date:  1995-09       Impact factor: 9.139

7.  Double trouble: impact of inappropriate use of asthma medication on the use of health care resources.

Authors:  A H Anis; L D Lynd; X H Wang; G King; J J Spinelli; M Fitzgerald; T Bai; P Paré
Journal:  CMAJ       Date:  2001-03-06       Impact factor: 8.262

Review 8.  Guidelines for the emergency management of asthma in adults. CAEP/CTS Asthma Advisory Committee. Canadian Association of Emergency Physicians and the Canadian Thoracic Society.

Authors:  R C Beveridge; A F Grunfeld; R V Hodder; P R Verbeek
Journal:  CMAJ       Date:  1996-07-01       Impact factor: 8.262

Review 9.  Cellular and immunological markers of allergic and intrinsic bronchial asthma.

Authors:  J C Virchow; C Kroegel; C Walker; H Matthys
Journal:  Lung       Date:  1994       Impact factor: 2.584

10.  Recent trends in the use of inhaled beta 2-adrenergic agonists and inhaled corticosteroids in Saskatchewan.

Authors:  B Habbick; M J Baker; M McNutt; D W Cockcroft
Journal:  CMAJ       Date:  1995-11-15       Impact factor: 8.262

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.